Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
24 7월 2023 - 8:00PM
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage
biopharmaceutical company leading a new treatment paradigm to
improve the lives of patients suffering from pruritus, today
announced the Company will host a conference call and live audio
webcast on Monday, August 7, 2023, at 4:30 p.m. ET to report second
quarter 2023 financial results and provide a corporate update.
To participate in the conference call, please
register here. Registrants will receive the dial-in numbers and a
unique PIN.
A live audio webcast and archived replay of the
call will be available under “Events & Presentations” in the
Investors section of the Company’s website at
www.CaraTherapeutics.com.
About Cara Therapeutics
Cara Therapeutics is a commercial-stage
biopharmaceutical company leading a new treatment paradigm to
improve the lives of patients suffering from pruritus. The
Company’s KORSUVA® (difelikefalin) injection is the first and only
FDA-approved treatment for moderate-to-severe pruritus associated
with chronic kidney disease in adults undergoing hemodialysis. The
Company is developing an oral formulation of difelikefalin and has
Phase 3 programs ongoing for the treatment of pruritus in patients
with advanced chronic kidney disease and atopic dermatitis. In
addition, the Company has initiated a Phase 2/3 program of oral
difelikefalin for the treatment of moderate-to-severe pruritus in
patients with notalgia paresthetica. For more information, visit
www.CaraTherapeutics.com and follow the company on Twitter,
LinkedIn and Instagram.
MEDIA CONTACT:Annie Spinetta6
Degrees973-768-2170aspinetta@6degreespr.com
INVESTOR CONTACT:Iris Francesconi, Ph.D.Cara
Therapeutics203-406-3700investor@caratherapeutics.com
Cara Therapeutics (NASDAQ:CARA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Cara Therapeutics (NASDAQ:CARA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024